165 related articles for article (PubMed ID: 38715141)
41. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
[TBL] [Abstract][Full Text] [Related]
42. New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.
Jing C; Wang T; Ma R; Cao H; Wang Z; Liu S; Chen D; Zhang J; Wu Y; Zhang Y; Wu J; Feng J
Mol Carcinog; 2020 May; 59(5):478-491. PubMed ID: 32141150
[TBL] [Abstract][Full Text] [Related]
43. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
[TBL] [Abstract][Full Text] [Related]
44. EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer.
Okada Y; Kimura T; Nakagawa T; Okamoto K; Fukuya A; Goji T; Fujimoto S; Sogabe M; Miyamoto H; Muguruma N; Tsuji Y; Okahisa T; Takayama T
Mol Cancer Res; 2017 Oct; 15(10):1445-1454. PubMed ID: 28698359
[TBL] [Abstract][Full Text] [Related]
45. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
Weng WH; Leung WH; Pang YJ; Hsu HH
Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
[TBL] [Abstract][Full Text] [Related]
46. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
[TBL] [Abstract][Full Text] [Related]
47. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
Cuyàs E; Queralt B; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Oncol Rep; 2017 Jul; 38(1):263-270. PubMed ID: 28560458
[TBL] [Abstract][Full Text] [Related]
48. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
[TBL] [Abstract][Full Text] [Related]
49. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
[TBL] [Abstract][Full Text] [Related]
50. Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS.
Ishida T; Ishii Y; Tsuruta M; Okabayashi K; Akimoto S; Koishikawa K; Hasegawa H; Kitagawa Y
Oncol Rep; 2017 Aug; 38(2):926-932. PubMed ID: 28656305
[TBL] [Abstract][Full Text] [Related]
51. CircRNA_0000392 promotes colorectal cancer progression through the miR-193a-5p/PIK3R3/AKT axis.
Xu H; Liu Y; Cheng P; Wang C; Liu Y; Zhou W; Xu Y; Ji G
J Exp Clin Cancer Res; 2020 Dec; 39(1):283. PubMed ID: 33317596
[TBL] [Abstract][Full Text] [Related]
52. MicroRNA-141-3p affected proliferation, chemosensitivity, migration and invasion of colorectal cancer cells by targeting EGFR.
Xing Y; Jing H; Zhang Y; Suo J; Qian M
Int J Biochem Cell Biol; 2020 Jan; 118():105643. PubMed ID: 31704502
[TBL] [Abstract][Full Text] [Related]
53. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer.
Nakajima TE; Boku N; Doi A; Arai H; Mizukami T; Horie Y; Izawa N; Hirakawa M; Ogura T; Tsuda T; Sunakawa Y
Invest New Drugs; 2020 Apr; 38(2):410-418. PubMed ID: 31020609
[TBL] [Abstract][Full Text] [Related]
54. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
Kim S; Kim N; Kang K; Kim W; Won J; Cho J
Cells; 2019 Aug; 8(8):. PubMed ID: 31409052
[TBL] [Abstract][Full Text] [Related]
55. Steroid receptor coactivator-3 regulates glucose metabolism in bladder cancer cells through coactivation of hypoxia inducible factor 1α.
Zhao W; Chang C; Cui Y; Zhao X; Yang J; Shen L; Zhou J; Hou Z; Zhang Z; Ye C; Hasenmayer D; Perkins R; Huang X; Yao X; Yu L; Huang R; Zhang D; Guo H; Yan J
J Biol Chem; 2014 Apr; 289(16):11219-11229. PubMed ID: 24584933
[TBL] [Abstract][Full Text] [Related]
56. MiR-103a-3p promotes tumour glycolysis in colorectal cancer via hippo/YAP1/HIF1A axis.
Sun Z; Zhang Q; Yuan W; Li X; Chen C; Guo Y; Shao B; Dang Q; Zhou Q; Wang Q; Wang G; Liu J; Kan Q
J Exp Clin Cancer Res; 2020 Nov; 39(1):250. PubMed ID: 33218358
[TBL] [Abstract][Full Text] [Related]
57. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
58. Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK/ERK signaling pathway.
Hua R; Zhang Y; Yan X; Tang D; Li X; Ni Q; Wang D; Zhu J
Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1547-1557. PubMed ID: 34596215
[TBL] [Abstract][Full Text] [Related]
59. Silencing Smad4 attenuates sensitivity of colorectal cancer cells to cetuximab by promoting epithelial‑mesenchymal transition.
Lin Z; Zhang L; Zhou J; Zheng J
Mol Med Rep; 2019 Oct; 20(4):3735-3745. PubMed ID: 31485652
[TBL] [Abstract][Full Text] [Related]
60. Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer.
Yu C; Hong H; Lu J; Zhao X; Hu W; Zhang S; Zong Y; Mao Z; Li J; Wang M; Feng B; Sun J; Zheng M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806905. PubMed ID: 30336768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
